Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $35.67 USD
Change Today -0.42 / -1.16%
Volume 74.9K
CHRS On Other Exchanges
As of 12:37 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

coherus biosciences inc (CHRS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/22/15 - $38.10
52 Week Low
11/6/14 - $12.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

coherus biosciences inc (CHRS) Related Businessweek News

No Related Businessweek News Found

coherus biosciences inc (CHRS) Details

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

75 Employees
Last Reported Date: 05/11/15
Founded in 2010

coherus biosciences inc (CHRS) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $450.2K
Chief Financial Officer
Total Annual Compensation: $102.4K
Chief Medical Officer
Total Annual Compensation: $443.0K
Chief Scientific Officer
Total Annual Compensation: $352.2K
Compensation as of Fiscal Year 2014.

coherus biosciences inc (CHRS) Key Developments

Coherus BioSciences, Inc. Enters an Office Lease with Hudson 333 Twin Dolphin Plaza, LLC; Obtains Standby Letter of Credit

Coherus BioSciences, Inc. entered into an office lease with Hudson 333 Twin Dolphin Plaza, LLC to lease approximately 27,532 square feet of office space located at 333 Twin Dolphin Drive, Redwood City, California for the company's new principal executive offices. The new lease commences on the earlier of (i) the first date on which tenant conducts business in the premises, or (ii) the later of (a) October 22, 2015, or (b) the date on which the landlord substantially completes certain improvements to the premises (the commencement date). The new lease terminates on the last day of the calendar month following the date that is eighty-four months after the commencement date, unless terminated earlier. The new lease provides for annual base rent of approximately $1.6 million in the first year of the lease term, which increases on a yearly basis up to approximately $1.9 million for the final year of the lease term. The company will also be obligated to pay to the landlord for certain costs, taxes and operating expenses related with the new lease and the premises, subject to certain exclusions. The company has obtained a standby letter of credit in the amount of approximately $0.8 million, which may be drawn down by the landlord to be applied for certain purposes upon the company's breach of any provisions under the new lease. Provided that no default occurs under the terms of the new lease, the company will be entitled to periodically reduce the amount of the letter of credit down to a maximum of approximately $0.3 million as of the last day of the sixtieth full calendar month of the lease term.

Coherus Biosciences, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 03:00 PM

Coherus Biosciences, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 03:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Coherus Biosciences, Inc. Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Coherus Biosciences, Inc. announced consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $5,810,000 compared with $3,596,000 for the same period a year ago. Loss from operations was $36,748,000 compared with $13,761,000 for the same period a year ago. Net loss attributable to Coherus was $40,725,000 or $1.22 per basic and diluted share compared with $25,170,000 or $6.03 per basic and diluted share for the same period a year ago. The higher revenue over the same period in 2014 was due to the recognition of increased Baxter collaboration revenue.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CHRS:US $35.67 USD -0.42

CHRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CHRS.
View Industry Companies

Industry Analysis


Industry Average

Valuation CHRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.3x
Price/Book 32.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COHERUS BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at